PAG
LXRX icon

Private Advisor Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Private Advisor Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-314
Closed -$1K – 2653
2020
Q2 		$1K Buy
+314
New +$615 ﹤0.01% 3725

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Private Advisor Group's LXRX Position: Q3 2020 in Review

Private Advisor Group sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2020, closing a stake of 314 shares — an estimated $1K sold.

Private Advisor Group first reported a position in LXRX in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 91 funds tracked by Wall St. Rank hold LXRX as of Q3 2020.

  • Private Advisor Group reported no remaining Lexicon Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 314 Lexicon Pharmaceuticals shares in Q3 2020, an estimated $1K.
  • Private Advisor Group first reported a position in Lexicon Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Lexicon Pharmaceuticals position peaked at $1K in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.